Madrigal Pharmaceuticals (MDGL) Revenue (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 6 years of Revenue data on file, last reported at $311.3 million in Q1 2026.

• On a quarterly basis, Revenue rose 126.84% year-over-year to $311.3 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 256.82% increase from a year earlier, with the FY2025 full-year figure at $958.4 million, up 432.05% from the prior year.
• Revenue for Q1 2026 stood at $311.3 million, down from $321.1 million in the prior quarter.
• Over the last five years, Revenue for MDGL reached as high as $321.1 million in Q4 2025 and fell as low as $14.6 million in Q2 2024.
• Historically, Revenue has averaged $181.2 million across 3 years, with a median of $175.0 million in 2025.
• Across the five-year window, Revenue surged 1353.76% in 2025 and jumped 126.84% in 2026, its largest moves.
• Year by year, Revenue stood at $103.3 million in 2024, then jumped by 210.77% to $321.1 million in 2025, then decreased by 3.04% to $311.3 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $311.3 million in Q1 2026, $321.1 million in Q4 2025, and $287.3 million in Q3 2025.